Burden of Administration: Belamaf Based Combinations (BVd, BPd) Versus Carfilzomib Based Combinations (IsaKd, DKd, Kd)
Author(s)
Yevgeniy SAMYSHKIN, MSc1, Molly Purser, PhD2, Ewa Dlotko, MSc3, Paul Macleod, MSc3, Katie Breslin, MSc3, Natalie Boytsov, PhD2, Simon McNamara, PhD4, Sandhya Sapra, PhD2, Attaya Suvannasankha, MD5;
1GSK, London, United Kingdom, 2GSK, Upper Providence, PA, USA, 3FIECON, London, United Kingdom, 4GSK, Stevenage, Hertfordshire, United Kingdom, 5Indiana University School of Medicine and Roudebush VA Medical Center, Indianapolis, IN, USA
1GSK, London, United Kingdom, 2GSK, Upper Providence, PA, USA, 3FIECON, London, United Kingdom, 4GSK, Stevenage, Hertfordshire, United Kingdom, 5Indiana University School of Medicine and Roudebush VA Medical Center, Indianapolis, IN, USA
Presentation Documents
OBJECTIVES: Belamaf is being investigated after first relapse or later in phase 3 RRMM studies: DREAMM-7 (NCT04246047; belamaf with bortezomib and dexamethasone [BVd]) and DREAMM-8 (NCT04484623; belamaf with pomalidomide and dexamethasone [BPd] in lenalidomide-exposed patients). The regimens demonstrated significant progression-free survival (both BVd/BPd) and overall survival (BVd) benefits, and 88% (DREAMM-7)/90% (DREAMM-8) of patients experienced extended dosing intervals, with administration burden reducing over the first year (Y). Administration burden in patients on treatment was evaluated for BVd/BPd versus intravenously (IV) administered second-line-or-later standards of care, IsaKd/DKd/Kd.
METHODS: A model estimating administration burden per patient receiving BVd/BPd/IsaKd/DKd/Kd for the first 2 years of treatment was developed. Dosing regimens were obtained using weekly individual patient-level dosing data from DREAMM-7/DREAMM-8 (BVd/BPd), and from published protocols (IsaKd/DKd/Kd). Administration burden inputs (administration number, clinic visits, and chair/monitoring [including ocular exam for BVd/BPd] durations) for the IV and subcutaneous (SC) agents were sourced from published protocols/clinician input. Oral pomalidomide/dexamethasone were assumed to not require administration visits. Reported results are means per patient on treatment.
RESULTS: For BVd, 9.1/9.7 IV belamaf/SC bortezomib administrations and 10.7 chair/monitoring hours were required in Y1, with 6.6/0.0 administrations and 6.6 hours in Y2. For BPd, 6.2 IV belamaf administrations and 6.2 chair/monitoring hours were required in Y1, with 3.3 administrations and 3.3 hours in Y2. For IsaKd, 28.0/78.0 IV isatuximab/carfilzomib administrations and 80.3 chair/monitoring hours were required in Y1, with 26.0/78.0 administrations and 78.0 hours in Y2. For DKd, 24.0/78.0 SC daratumumab/IV carfilzomib administrations and 70.3 chair/monitoring hours were required in Y1, with 13.0/78.0 administrations and 67.2 hours in Y2. Kd required 78.0 IV carfilzomib administrations in each year, with 66.3 (Y1) and 65.0 (Y2) chair/monitoring hours. Sensitivity analyses were consistent with primary analyses. Alternative administration times and costs were also explored.
CONCLUSIONS: BVd/BPd are associated with substantially lower administration burden versus IsaKd/DKd/Kd. Funding: GSK
METHODS: A model estimating administration burden per patient receiving BVd/BPd/IsaKd/DKd/Kd for the first 2 years of treatment was developed. Dosing regimens were obtained using weekly individual patient-level dosing data from DREAMM-7/DREAMM-8 (BVd/BPd), and from published protocols (IsaKd/DKd/Kd). Administration burden inputs (administration number, clinic visits, and chair/monitoring [including ocular exam for BVd/BPd] durations) for the IV and subcutaneous (SC) agents were sourced from published protocols/clinician input. Oral pomalidomide/dexamethasone were assumed to not require administration visits. Reported results are means per patient on treatment.
RESULTS: For BVd, 9.1/9.7 IV belamaf/SC bortezomib administrations and 10.7 chair/monitoring hours were required in Y1, with 6.6/0.0 administrations and 6.6 hours in Y2. For BPd, 6.2 IV belamaf administrations and 6.2 chair/monitoring hours were required in Y1, with 3.3 administrations and 3.3 hours in Y2. For IsaKd, 28.0/78.0 IV isatuximab/carfilzomib administrations and 80.3 chair/monitoring hours were required in Y1, with 26.0/78.0 administrations and 78.0 hours in Y2. For DKd, 24.0/78.0 SC daratumumab/IV carfilzomib administrations and 70.3 chair/monitoring hours were required in Y1, with 13.0/78.0 administrations and 67.2 hours in Y2. Kd required 78.0 IV carfilzomib administrations in each year, with 66.3 (Y1) and 65.0 (Y2) chair/monitoring hours. Sensitivity analyses were consistent with primary analyses. Alternative administration times and costs were also explored.
CONCLUSIONS: BVd/BPd are associated with substantially lower administration burden versus IsaKd/DKd/Kd. Funding: GSK
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
SA25
Topic
Study Approaches
Topic Subcategory
Decision Modeling & Simulation
Disease
SDC: Oncology